Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003

PHASE3CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

July 10, 2015

Primary Completion Date

October 10, 2016

Study Completion Date

October 10, 2016

Conditions
OsteoarthritisPain
Interventions
DRUG

Placebo

Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.

DRUG

Fulranumab 1 mg

Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.

DRUG

Fulranumab 3 mg

Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.

Trial Locations (28)

Unknown

El Cajon

Sherman Oaks

Miami

Traverse City

Omaha

Cincinnati

San Antonio

Leuven

Newmarket

Windsor

Montreal

Prague

Uherské Hradiště

Almere Stad

Bialystok

Gdynia

Poznan

Warsaw

Wroclaw

Zgierz

Alcalá de Henares

Barcelona

Madrid

Santiago de Compostela

Blackpool

Cannock

Mancheter

Stourton

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02289716 - Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003 | Biotech Hunter | Biotech Hunter